CD38-directed human IgG1 monoclonal antibody that depletes CD38+ plasma cells via ADCC, CDC, ADCP, and apoptosis and modulates the immune microenvironment.
Daratumumab is a CD38-directed human IgG1 monoclonal antibody that binds CD38 on plasma cells, inducing antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis, while depleting CD38+ immunosuppressive cells and modulating the tumor immune microenvironment.
YES
DIRECT
Anti-CD38 IgG1 binds CD38 on target cells and mediates NK-cell ADCC, complement-dependent cytotoxicity (CDC), macrophage ADCP, and can induce apoptosis upon binding/crosslinking.
CD30-directed antibody-drug conjugate delivering MMAE to malignant cells to disrupt microtubules and induce apoptosis.
CD30-directed monoclonal antibody linked via a valine-citrulline linker to the microtubule-disrupting payload monomethyl auristatin E (MMAE). After binding CD30 and internalization, lysosomal cleavage releases MMAE, which inhibits tubulin polymerization, causing G2/M arrest and apoptosis of CD30-positive malignant cells.
YES
DIRECT
The ADC binds CD30, is internalized, and releases MMAE via lysosomal cleavage; MMAE inhibits tubulin polymerization, causing G2/M arrest and apoptosis of CD30+ cells.
CD30-directed antibody-drug conjugate delivering MMAE to malignant cells to disrupt microtubules and induce apoptosis.
CD30-directed monoclonal antibody linked via a valine-citrulline linker to the microtubule-disrupting payload monomethyl auristatin E (MMAE). After binding CD30 and internalization, lysosomal cleavage releases MMAE, which inhibits tubulin polymerization, causing G2/M arrest and apoptosis of CD30-positive malignant cells.
NO
INDIRECT
Brentuximab vedotin targets CD30, is internalized, and releases MMAE, which binds beta-tubulin to inhibit microtubule polymerization, causing mitotic arrest and apoptosis. Tubulin is the intracellular payload target, not the antigen determining selective killing.
A HER2-targeted antibody–drug conjugate in which a monoclonal antibody binds HER2 (ERBB2) on tumor cells, is internalized, and releases the cytotoxic payload monomethyl auristatin E (MMAE) to disrupt microtubules and induce apoptosis; may exert a bystander effect.
HER2-targeted antibody–drug conjugate: an anti-HER2 monoclonal antibody binds ERBB2 on tumor cells, is internalized, and a cleavable linker releases the cytotoxic payload MMAE, a microtubule inhibitor, causing mitotic arrest and apoptosis; the membrane-permeable payload may produce a bystander effect.
YES
DIRECT
The ADC binds HER2 on target cells, is internalized, and releases MMAE, which inhibits microtubules, causing mitotic arrest and apoptosis; the membrane-permeable payload can also produce a bystander effect.
A HER2-targeted antibody–drug conjugate in which a monoclonal antibody binds HER2 (ERBB2) on tumor cells, is internalized, and releases the cytotoxic payload monomethyl auristatin E (MMAE) to disrupt microtubules and induce apoptosis; may exert a bystander effect.
HER2-targeted antibody–drug conjugate: an anti-HER2 monoclonal antibody binds ERBB2 on tumor cells, is internalized, and a cleavable linker releases the cytotoxic payload MMAE, a microtubule inhibitor, causing mitotic arrest and apoptosis; the membrane-permeable payload may produce a bystander effect.
NO
INDIRECT
RC48-ADC targets HER2 on the cell surface, is internalized, and releases MMAE, which binds beta-tubulin to disrupt microtubules and induce mitotic arrest/apoptosis; killing depends on HER2-mediated delivery (with possible bystander effect), not on beta-tubulin expression per se.